Prof.張偉嶠’s CV

Wei-Chiao Chang (張偉嶠)

Distinguished Professor/Vice Dean, School of Pharmacy, School of Pharmacy, Taipei Medical University


Master Program for Clinical Pharmacogenomics and Pharmacoproteomics

Dr. Wei-Chiao Chang (D.Phil. Oxon) is a distinguished professor of Taipei Medical University. He obtained his doctoral degree at University of Oxford, UK (2007). During his Ph.D. study, his findings indicated a sub-plasmalemmal calcium increase via store-operated calcium channel (SOC) is able to activate temporally and spatially distinct responses, increasing its versatility in driving fundamental cellular responses (J Biol Chem. 2008; J Immunol. 2007 FASEB J. 2006; J Biol Chem. 2004). After his Ph.D. study, he was recruited by Prof. Yusuke Nakamura to join RIKEN Center for Genomic Medicine, Japan. In 2007, he was awarded the position of International Research Scientist (FY2008) by RIKEN. In 2009, Dr. Chang moved back to Taiwan and worked as an Assistant Professor in Kaohsiung Medical University. He was supported by the NSC Distinguished Young Scientist Project (2010~). In 2012, he moved his lab to Taipei Medical University. With generous support from Taipei Medical University, he established the first M.S. program for Clinical Pharmacogenomics and Pharmacoproteomics in Taiwan. Dr. Chang mastered a variety of experimental techniques (DNA sequencing, GWAS, biophysical analysis, immunosequencing) and has used a combination of methods to develop his research. In the past three years (2015~2018), Dr. Chang has published several corresponding author papers in prestigious journals, including Oncogene (2015), Oncoimmunology (two; 2016 and 2018), Pharmacol Res (2016), Circ: Cardiovasc Genet (2016), Cancer Epidemiol Biomarkers Prev. (2018) and Am J Pathol (2015). Dr. Chang is not only a scientist, but he is also a talented writer who has published many books (未來基因體醫療; 情繫牛津 (second edition); Chronic Inflammation: Causes, Treatment Options and Role in Disease) that can be widely seen in the internet bookstores. The proceeds from the copyright on “情繫牛津” are used to support the “Make a Wish Foundation”(喜願基金會), which grants life-changing wishes for children with critical illnesses. “These children have so little time” Dr. Chang always says. “We have to process a lot of material into just one drop of useful product in the lab. So, we should do our best to speed up the process, to help the kids, to turn many tears into smiles – at least once.”

Selective publications within three years (*corresponding author):

  1. Wong HS, Chang WC*. Losses of cytokines and chemokines are common genetic features of human cancers: the somatic copy number alterations are correlated with patient prognoses and therapeutic resistance. 2018 Jul 30;7(9):e1468951. (IF:7.7)
  2. Ho KH, Chang CK, Chen PH, Wang YJ, Chang WC*, Chen KC*. miR-4725-3p targeting stromal interacting molecule 1 signaling is involved in xanthohumol inhibition of glioma cell invasion. J Neurochem. 2018 Aug;146(3):269-288. (IF:4.6)
  3. Kuo CN, Pan JJ, Huang YW, Tsai HJ*, Chang WC*. Association between Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer: A Population-Based Case-Control Study. Cancer Epidemiol Biomarkers Prev. 2018 Jul;27(7):737-745. (IF:4.5)
  4. Kuo HC, Wong HS, Chang WP, Chen BK, Wu MS, Yang KD, Hsieh KS, Hsu YW, Liu SF, Liu X, Chang WC*. Prediction for Intravenous Immunoglobulin Resistance by Using Weighted Genetic Risk Score Identified From Genome-Wide Association Study in Kawasaki Disease. Circ Cardiovasc Genet. 2017 ;10(5). pii: e001625. (IF:5.6)
  5. Wong HS, Chang CM, Liu X, Huang WC, Chang WC*. Characterization of cytokinome landscape for clinical responses in human cancers. 2016 ;5(11):e1214789. (IF:7.7)
  6. Klahan S, Huang WC, Chang CM, Wong HS, Huang CC, Wu MS, Lin YC, Lu HF, Hou MF, Chang WC*. Gene expression profiling combined with functional analysis identify integrin beta1 (ITGB1) as a potential prognosis biomarker in triple negative breast cancer. Pharmacol Res. 2016;104:31-7. (IF:4.8)
  7. Wang JY, Sun J, Huang MY, Wang YS, Hou MF, Sun Y, He H, Krishna N, Chiu SJ, Lin S, Yang S*, Chang WC*. STIM1 overexpression promotes colorectal cancer progression, cell motility and COX-2 expression. Oncogene. 2015 Aug 13:34(33):4358-67 (IF:7.9)
  8. Juan YS, Lee YL, Long CY, Wong JH, Jang MY, Lu JH, Wu WJ, Huang YS, Chang WC*, Chuang SM*. Translocation of NF-κB and expression of cyclooxygenase-2 are enhanced by ketamine-induced ulcerative cystitis in rat bladder. Am J Pathol. 2015 Aug;185(8):2269-85. (IF: 4.2)
Share Button

Comments are closed.